Elizabeth P Taras

发表

In vivo imaging of graft-versus-host-disease in mice.

J. Serody, A. Panoskaltsis-Mortari, B. Blazar, 2004, Blood.

Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy.

A. Panoskaltsis-Mortari, D. Vallera, A. Sicheneder, 2009, Leukemia research.

Targeting pediatric sarcoma with a bispecific ligand immunotoxin targeting urokinase and epidermal growth factor receptors

D. Vallera, T. DeFor, A. Borgatti, 2017, Oncotarget.

Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker.

Jeffrey S. Miller, D. Vallera, M. Felices, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

Impact of Repeated Cycles of EGF Bispecific Angiotoxin (eBAT) Administered at a Reduced Interval from Doxorubicin Chemotherapy in Dogs with Splenic Hemangiosarcoma.

J. Koopmeiners, J. Modiano, D. Vallera, 2020, Veterinary and comparative oncology.

Acceleration of idiopathic pneumonia syndrome (IPS) in the absence of donor MIP-1 alpha (CCL3) after allogeneic BMT in mice.

J. Serody, A. Panoskaltsis-Mortari, B. Blazar, 2003, Blood.

Post-BMT lung injury occurs independently of the expression of CCL2 or its receptor, CCR2, on host cells.

B. Rollins, I. Charo, B. Blazar, 2004, American journal of physiology. Lung cellular and molecular physiology.

(CCL3) post-allogeneic BMT in mice α donor MIP-1 Acceleration of idiopathic pneumonia syndrome (IPS) in the absence of

J. Hermanson, Elizabeth P Taras, O. Wangensteen, 2012 .

Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker

Jeffrey S. Miller, D. Vallera, D. Todhunter, 2016, Oncotarget.

Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.

A. Skubitz, D. Vallera, Elizabeth P Taras, 2013, Gynecologic oncology.

Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies

V. Bachanova, D. Vallera, D. Todhunter, 2018, Toxins.

Radiotherapy of CD45-expressing Daudi tumors in nude mice with yttrium-90-labeled, PEGylated anti-CD45 antibody.

M. Brechbiel, D. Vallera, L. Burns, 2007, Cancer biotherapy & radiopharmaceuticals.

CD16-IL15-CD33 Trispecific Killer Engager (TriKE) Overcomes Cancer-Induced Immune Suppression and Induces Natural Killer Cell-Mediated Control of MDS and AML Via Enhanced Killing Kinetics

J. Tolar, Jeffrey S. Miller, S. Spellman, 2016 .

Trispecific Killer Engagers (TriKEs) that contain IL-15 to make NK cells antigen specific and to sustain their persistence and expansion

J. Tolar, Bin Zhang, Jeffrey S. Miller, 2015 .

Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin

D. Vallera, D. Todhunter, A. Borgatti, 2018, Clinical pharmacology : advances and applications.

In vivo imaging of graft-versus-host-disease in mice.

J. Serody, B. Blazar, Andrew P. Price, 2004, Blood.